Skip to Main Content

The pharmaceutical industry’s largest lobbying organization released guidelines on Tuesday to enhance racial and ethnic diversity among participants in clinical trials run by its member drug makers. The principles address a problem that has long hampered the development of new medicines and vaccines, including the studies of potential Covid-19 shots.

The group, PhRMA, noted that the guidelines are voluntary; they do not take effect until April 2021.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!